1.A STUDY ON THE CHANGE THE UPPER LIP AFTER SAGITTAL SPLIT RAMUS OSTEOTOMY
Soon Seop WOO ; Hyun Chul WE ; Young Soo LEE ; Kwang Sup SHIM
Journal of the Korean Association of Maxillofacial Plastic and Reconstructive Surgeons 1999;21(1):35-40
we studied the 12 patients, operated only sagittal split ramus osteotomy without genioplasty or maxillary osteotomy in department of oral and maxillofacial surgery, Hanyang university hospital from 1996.1. 1. to 1998. 7. 20. Preoperative and postoperative cephalometric view was measured to know the change of upper lip position and shape after mandibular setback. The result were obtained as follows. 1. The ratio of upper lip change amount to lower incisor horizontal movement was 15.1%. 2. The ratio of lower facial profile between Sn-Stm and Stm-Mes was changed from 1 : 2.352 to 1 : 2.069 after operation. 3. Post-operative upper lip was flattened 72.4% compared with pre-opreative one. 4. The vermilion zone of the upper lip increased 56% horizontally, 5.8% vertically after operation. 5. The vermilion zone ratio of the lower lip to the upper lip was change from 1 : 1.253 to 1 : 1.348. 6. The distance between esthetic line and Ls was changed from -3.958mm to -1.15mm.]]>
Genioplasty
;
Humans
;
Incisor
;
Lip
;
Maxillary Osteotomy
;
Orthognathic Surgery
;
Osteotomy
;
Osteotomy, Sagittal Split Ramus
;
Prognathism
;
Surgery, Oral
2.Survey on the Awareness of Guardians of Young Infants on the Weaning of Food in Pohang and Gyeongju Area.
Hyun Woo WE ; Yu Kyung SEO ; Ae Suk KIM ; Sun Ju LEE ; Sung Min CHO ; Dong Seok LEE ; Doo Kwun KIM ; Sung Min CHOI
Korean Journal of Pediatric Gastroenterology and Nutrition 2006;9(2):233-241
PURPOSE: This study was carried out to investigate the awareness of the weaning of food using questionnaires, and the relationship with the weight gain in young infants. METHODS: From September 2005 to December 2005, we performed a survey on 141 guardians of young infants aged from 6 to 18 months, who visited the pediatric out-patient department at Dongguk University Medical Center. We calculated the total score for each responder from ten questions on the weaning of food and assessed the body weight percentile of each of the young infants. RESULTS: The most commonly reported information source for weaning food was 'the friends around' by 62 respondents (44.0%); 54 (38.3%) responded that the definition of weaning food was the preparatory step before starting a solid diet. Most used a spoon (90.8%) to feed when weaning food with a thin gruel of rice (78.7%). The time for weaning of food was before breast or infant formula feeding (55.3%). Addition of cow's milk was around 12 months (77.3%). The mean score was 6.21; however this did not show a statistically significant correlation with weight gain in young infants. CONCLUSION: The overall awareness of weaning of food has improved; however, information from doctors has decreased. Although the relationship between the awareness of weaning of food and the growth of young infants was not statistically significant, further studies on weaning of food, with larger and controlled sample sizes may provide important information.
Academic Medical Centers
;
Body Weight
;
Breast
;
Surveys and Questionnaires
;
Diet
;
Friends
;
Gyeongsangbuk-do*
;
Humans
;
Infant Formula
;
Infant*
;
Milk
;
Outpatients
;
Sample Size
;
Weaning*
;
Weight Gain
3.Renal Parenchymal Malakoplakia Presenting with Abscesses and Hepatic Extension Misdiagnosed as a Malignant Tumor: A Case Report.
Sun Young YOON ; Hyo Jeong LEE ; Ji Hyun AN ; Su Jeong KIM ; Sang We KIM ; Jun Hee WOO ; Yang Soo KIM
Korean Journal of Medicine 2012;82(6):764-768
Malakoplakia is a chronic inflammatory disorder that usually affects the urinary tract in immunocompromised patients and rarely extends to adjacent organs. Due to its mass-like presentation, malakoplakia is often clinically misdiagnosed as a neoplastic lesion. We describe the case of a 51-year-old female with renal malakoplakia and hepatic extension and large intraperitoneal abscesses that had been misdiagnosed as malignancy. She was diagnosed with myasthenia gravis 12 years prior and had been treated with oral corticosteroids and immunosuppressants. Radical nephrectomy concomitant with abscess drainage was performed. The final pathology was compatible with malakoplakia, and the patient was successfully treated with antibiotics. Although renal malakoplakia is a rare disease, it should be included in the differential diagnosis of patients with a renal mass who have a history of recurrent urinary tract infections or evidence of immunosuppression.
Abscess
;
Adrenal Cortex Hormones
;
Anti-Bacterial Agents
;
Diagnosis, Differential
;
Drainage
;
Female
;
Humans
;
Immunocompromised Host
;
Immunosuppression
;
Immunosuppressive Agents
;
Kidney
;
Liver
;
Malacoplakia
;
Middle Aged
;
Myasthenia Gravis
;
Nephrectomy
;
Rare Diseases
;
Urinary Tract
;
Urinary Tract Infections
4.Renal Parenchymal Malakoplakia Presenting with Abscesses and Hepatic Extension Misdiagnosed as a Malignant Tumor: A Case Report
Sun Young YOON ; Hyo Jeong LEE ; Ji Hyun AN ; Su Jeong KIM ; Sang We KIM ; Jun Hee WOO ; Yang Soo KIM
Korean Journal of Medicine 2012;82(6):764-768
Malakoplakia is a chronic inflammatory disorder that usually affects the urinary tract in immunocompromised patients and rarely extends to adjacent organs. Due to its mass-like presentation, malakoplakia is often clinically misdiagnosed as a neoplastic lesion. We describe the case of a 51-year-old female with renal malakoplakia and hepatic extension and large intraperitoneal abscesses that had been misdiagnosed as malignancy. She was diagnosed with myasthenia gravis 12 years prior and had been treated with oral corticosteroids and immunosuppressants. Radical nephrectomy concomitant with abscess drainage was performed. The final pathology was compatible with malakoplakia, and the patient was successfully treated with antibiotics. Although renal malakoplakia is a rare disease, it should be included in the differential diagnosis of patients with a renal mass who have a history of recurrent urinary tract infections or evidence of immunosuppression.
Abscess
;
Adrenal Cortex Hormones
;
Anti-Bacterial Agents
;
Diagnosis, Differential
;
Drainage
;
Female
;
Humans
;
Immunocompromised Host
;
Immunosuppression
;
Immunosuppressive Agents
;
Kidney
;
Liver
;
Malacoplakia
;
Middle Aged
;
Myasthenia Gravis
;
Nephrectomy
;
Rare Diseases
;
Urinary Tract
;
Urinary Tract Infections
5.A Case of Hereditary C7 Deficiency Associated with Meningococcal Meningitis.
Hyun Woo WE ; Won Duck KIM ; Sun Ju LEE ; Dong Seok LEE ; Doo Kwun KIM ; Sung Min CHOI ; Gyoung Yim HA
Korean Journal of Pediatrics 2004;47(7):799-802
The complement system is composed of more than 25 different proteins and is usually divided into classical and alternative pathways. Complement component 7(C7) is one of the five terminal complement proteins that, upon activation of either the classical or the alternative pathway, interacts sequentially to form a large protein-protein complex, called membrane attack complex(MAC). Assembly of the MAC on target cells results in the formation of transmembrane pores that can lead to the killing of the cells. C7 deficiency is an autosomal recessive disorder that is mostly reported in Caucasians. The gene for C7 has been assigned to chromosome 5p13. To date, 15 different molecular defects leading to total or subtotal C7 deficient defects have been reported. C7 deficiency is associated frequently with recurrently bacterial infections, especially meningitis caused by Neisseria meningitidis. We report a case of a hereditary C7 deficiency associated with meningococcal meningitis.
Bacterial Infections
;
Complement C7
;
Complement System Proteins
;
Homicide
;
Membranes
;
Meningitis
;
Meningitis, Meningococcal*
;
Neisseria meningitidis
6.Nuclear Hyperploidy of Megakaryocytes and Platelet Aggregation Test in Essential Thrombocythemia.
Young Rok SHIN ; Cheolwon SUH ; Byung Min JUN ; Jeong Hee HAN ; Suk Sue LEE ; Hyun Young KIM ; Tae Won KIM ; Je Hwan LEE ; Sung Bae KIM ; Sang We KIM ; Kyoo Hyung LEE ; Jung Shin LEE ; Woo Kun KIM ; Sang Hee KIM ; Chan Jeoung PARK ; Hyun Sook CHI
Korean Journal of Hematology 1999;34(4):568-572
BACKGROUND: Essential thrombocythemia (ET) is a rare chronic myeloproliferative disorder characterized by an extremely high platelet count in the circulating blood and abnormal proliferation of the megakaryocytes in bone marrow, resulting in splenomegaly, thromboembolic or hemorrhagic complications. We studied the presence of nuclear hyperploidy of the megakaryocytes in bone marrow, the presence of abnormal response to the individual reagent on platelet aggregation test, and its clinical implication. METHODS: We analyzed the 43 cases of ET at the Asan Medical Center between January, 1989 and March, 1999. The Polycythemia Vera Study Group criteria were used to diagnose ET. RESULTS: Nuclear hyperploidy was observed at 43 cases (100%). Platelet aggregation test was done at 32 (74.4%) cases, of which 27 (84.4%) cases showed abnormal response to more than one reagent, 16 (50%) cases to more than two reagents. Abnormal response to epinephrine and collagen was most common, but 5 cases showed normal response. By individual reagent, 1 (3%) cases to adenosine diphosphate, 1 (3%) case to ristocetin, 22 (69%) cases to epinephrine, 19 (59%) cases to collagen showed abnormal response. CONCLUSION: We observe that nuclear hyperploidy of the megakaryocyts and abnormal response on platelet aggregation test are frequent in ET in this study.
Adenosine Diphosphate
;
Blood Platelets*
;
Bone Marrow
;
Chungcheongnam-do
;
Collagen
;
Epinephrine
;
Indicators and Reagents
;
Megakaryocytes*
;
Myeloproliferative Disorders
;
Platelet Aggregation*
;
Platelet Count
;
Polycythemia Vera
;
Ristocetin
;
Splenomegaly
;
Thrombocythemia, Essential*
7.High-Dose Chemotherapy of Cyclophosphamide, Thiotepa, and Carboplatin (CTCb) with Autologous Peripheral Blood Stem Cell Transplantation for High-Risk Primary Breast Cancer and Metastatic Breast Cancer.
Young Joo MIN ; Cheol Won SUH ; Je Hwan LEE ; Young Ran CHAE ; Shin KIM ; Chang Whang BAE ; Jin Hee PARK ; Sung Joon CHOI ; Tae Won KIM ; Whan Jung YOON ; Byung Hak JUNG ; Dai Young ZANG ; Jong Soo CHOI ; Sung Bae KIM ; Sang We KIM ; Kyoo Hyung LEE ; Jung Shin LEE ; Woo Kun KIM ; Sei Hyun AHN ; Jung Mi PARK ; Sang Hee KIM
Korean Journal of Medicine 1997;53(4):482-487
OBJECTIVES: Recently high dose chemotherapy with autologous peripheral blood stem cell transplantation (APBSCT) has been investigated with the hope of maximizing tumor response and increasing survival. The purpose of this study is to evaluate the effect, feasibility, and toxicity of high-dose cyclophosphamide, thiotepa, and carboplatin (CTCb) with APBSCT in patients with metastatic or high risk primary breast cancer. METHODS: Four cases of high-risk primary breast cancer (with more than 10 involved axillary nodes) and three cases of metastatic disease in complete or partial response were enrolled. Peripheral blood stem cells were mobilized by G-CSF plus chemotherapy, and median number of collected mononuclear cells was 5.44 X 108/kg(range, 1.95-7.08 X 108/kg). High-dose chemotherapy of cyclophosphamide (1,500mg/m2/day), thiotepa (125mg/m2/day) and carboplatin (200mg/m2/day) was administered for 4 days and peripheral blood stem cells were reinfused to the patients 72 hours after the completion of chemotherapy. RESULTS: The median days of recovery for neutrophil (over 500/mm3) and for platelet (over 50,000/mm3) were 10 (range, 8 to 33) and 30 (range, 10 to 40). One patient suffered from seizure attack and grade 3 hepatotoxicity during high dose chemotherapy, There were no treatment-related death. Four patients with high-risk primary breast cancer remained disease-free at 2, 8, 12 and 19 months post-transplant. In one patient with bone metastasis, complete response was induced following APBSCT. All three patients with metastatic disease remained progression-free at 8, 18 and 19 months post-transplant. CONCLUSION: High-dose chemotherapy and autologous peripheral blood stem cell transplantation was feasible and would be a potentially effective treatment modality in high risk and metastatic breast cancer.
Blood Platelets
;
Breast Neoplasms*
;
Breast*
;
Carboplatin*
;
Cyclophosphamide*
;
Drug Therapy*
;
Granulocyte Colony-Stimulating Factor
;
Hope
;
Humans
;
Neoplasm Metastasis
;
Neutrophils
;
Peripheral Blood Stem Cell Transplantation*
;
Seizures
;
Stem Cells
;
Thiotepa*
8.Prognostic factors affecting response to chemotherapy and survival duration in Korean patients with multiple myeloma.
Hun Ho SONG ; Je Hwan LEE ; Jong Beom PARK ; Seong Jun CHOI ; Jeong Kyoon KIM ; Sung Bae KIM ; Sang We KIM ; Cheol Won SUH ; Kyoo Hyung LEE ; Jung Shin LEE ; Woo Kun KIM ; Chan Jeong PARK ; Hyun Sook CHI ; Sang Hee KIM
Korean Journal of Medicine 2000;58(1):83-90
BACKGROUND: New therapeutic modalities such as high dose chemotherapy and stem cell support have been tried to prolong the survival period of the patients with multiple myeloma. However, little is known about the criteria for the application of those new therapies. There are only a few reports for the prognostic factors of multiple myeloma in Korea. The purpose of this study is to analyze the prognostic factors affecting chemotherapy response and survival in patients with multiple myeloma. METHODS: We retrospectively analysed the clinical records of 122 patients who were newly diagnosed as multiple myeloma by SWOG criteria, between November, 1989 and April, 1997 at Asan Medical Center. RESULTS: 1) The peak incidence was the 7th decade and male to female ratio was 1.3:1. The most common presenting symptom at first diagnosis was bone pain. 2) Initial clinical stage was as followed: stage I in 17.2% , stage II in 16.4% and 66.4% in III. The immunoglobulin classes were IgG in 51.6%, light chain only in 25.4%, IgA in 16.4%, IgD in 4.1%, and non-secretory type in 2.5%. Plasma cell types in bone marrow were classified as plasmablastic type in 45.9%, plasmacytic type in 54.1%. 3) Eighty two patients who recieved chemotherapy more than 3 cycles were evaluable for chemotherapy response. Overall response rate was 69.5%. Factors affecting response to chemotherapy were serum creatinine level, plasma cell type, total plasma cell percentage and plasmablast percentasge of total nucleated cells in bone marrow. 4) For total 122 patients, overall median survival period was 21 months, and estimated 5 year survival rate was 23.5%. Factors affecting survival were serum creatinine, corrected calcium, albumin, beta2-microglobulin level, response to chemotherapy, total plasma cell percentage and plasmablast percentage in bone marrow. CONCLUSION: Bone marrow findings at initial diagnosis are significantly associated with response to chemotherapy and survival duration.
Bone Marrow
;
Calcium
;
Chungcheongnam-do
;
Creatinine
;
Diagnosis
;
Drug Therapy*
;
Female
;
Humans
;
Immunoglobulin A
;
Immunoglobulin D
;
Immunoglobulin G
;
Immunoglobulin Isotypes
;
Incidence
;
Korea
;
Male
;
Multiple Myeloma*
;
Plasma Cells
;
Retrospective Studies
;
Stem Cells
;
Survival Rate
9.A Case of Treatment-Related Myelodysplastic syndrome and Acute Myelogenous Leukemia Following High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Non-Hodgkin's Lymphoma.
Geun Doo JANG ; Sang We KIM ; Cheol Won SUH ; Eun Kyoung KIM ; Hye Seung BAHNG ; Young Hoon JEONG ; Il Gwon PARK ; Woo Kun KIM ; Sang Hee KIM ; Eul Ju SUH ; Chan Jeoung PARK ; Hyun Sook JI ; Jung Shin LEE
Journal of Korean Medical Science 2002;17(4):555-559
Treatment-related myelodysplastic syndrome (t-MDS) and acute myelogenous leukemia (t-AML) are now well established as complications of cytotoxic chemotherapy. We experienced a 28-yr-old female patient who developed t-MDS/t-AML with characteristic chromosomal abnormalities including 11q23 chromosomal rearrangement following high-dose chemotherapy with autologous stem cell transplantation (ASCT) for non-Hodgkin's lymphoma. The patient was admitted with bulky abdominal masses of B cell lineage non-Hodgkin's lymphoma. After 2 cycles of systemic chemotherapy of the Vanderbilt regimen, the patient underwent ASCT with high dose chemotherapy of the BEAC regimen. She also received radiation of 48 Gy for the residual periportal lymphadenopathy. The initial cytogenetic analysis of the infused mononuclear cells revealed a normal karyotype. Twenty two months after the ASCT, pancytopenia was noted and her bone marrow aspirate showed dysplastic hemopoiesis with myeloblasts up to 12% of nonerythroid nucleated cells. The patient was diagnosed as t-MDS (refractory anemia with an excess of blasts). Cytogenetic analysis showed complex chromosomal abnormalities including 11q23 rearrangement, which is frequently found in topoisomerase II inhibitor-related hematologic malignancies. Four months later, it was noted that the t-MDS had evolved into an overt t-AML. Cytogenetic analysis showed an evolving pattern with more complex abnormalities. The patient was treated with combination che-motherapy, but her leukemic cells were resistant to the therapy.
Adult
;
Antineoplastic Agents, Phytogenic/adverse effects
;
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
;
B-Lymphocytes/cytology
;
Bone Marrow Cells/pathology
;
Carmustine/*adverse effects
;
Chromosome Aberrations
;
Chromosomes, Human, Pair 11
;
Combined Modality Therapy/adverse effects
;
Cyclophosphamide/*adverse effects
;
Cytarabine/*adverse effects
;
Etoposide/*adverse effects
;
Female
;
Gene Rearrangement
;
Hematopoietic Stem Cell Transplantation/*adverse effects
;
Humans
;
Leukemia, Myeloid, Acute/*etiology/genetics
;
Lymphoma, Non-Hodgkin/*therapy
;
Myelodysplastic Syndromes/*etiology/genetics
;
Neoplasms, Second Primary/*etiology
;
Pelvis
;
Pregnancy
;
Pregnancy Complications, Neoplastic/*therapy
;
Transplantation, Autologous
10.Hyperfractionated Radiotherapy and Concurrent Chemotherapy for Stage III Unreasectabel Non Small Cell Lung Cancer: Preliminary Report for Response and Toxicity.
Eun Kyung CHOI ; Jong Hoon KIM ; Hyesook CHANG ; Sang We KIM ; Cheolwon SUH ; Kyoo Hyung LEE ; Jung Shin LEE ; Sang Hee KIM ; Youn Suk KO ; Woo Sung KIM ; Dong Soon KIM ; Won Dong KIM ; Koun Sik SONG ; Seung Il PARK ; Kwang Hyun SOHN
Journal of the Korean Society for Therapeutic Radiology 1995;13(2):157-162
Lung cancer study group at Asan Medical Center has conducted the second prospective study to determine the efficacy and feasibility of MVP chemotherapy with concurrent hyperfractionated radiotherapy for patients with stage III unresectable non-small cell lung cancer(NSCLC). All eligible patients with stage III unresectable NSCLC were treated with hyperfractionated radiotherapy( 120 cGy/fx BID, 6480 cGY/54fx) and concurrent 2 cycles of MVP(Motomycin C 6 mg/m2 , d2 & d29, Vinblastin 6 mg/m2, d2 & d29, Cisplatin 6 mg/m2 , d1 & d28) chemotherapy. Between Aug. 1993 and Nov. 1994, 62 patients entered this study ; 6(10%) had advanced stage IIIa and 56(90%) had IIIb disease including 1 with pleural effusion and 10 with supraclavicular metastases. Among 62 Ptients, 48(77%) completed planned therapy. Fourteen patients refused further treatment during chemoradiotherapy. Of 46 patients evaluable for response, 34(74%) showed major response including 10(22%) with complete and 24(52%) with partial responses. Of 48 patients evaluable for toxicity, 13(27%) showed grade IV hematologic toxicity but treatment delay did not exceed 5 days. Two patients died of sepsis during chemoradiotherapy. Server weight(more than 10%) occurred in 9 patients(19%) during treatment. Nine patients(19%) developed radiation pneumonitis. Six of these patients had grad I(mild) pneumonitis with radiographic changes within the treatment fields. Three other patients had grade II pneumonitis, but none of theses patients had continuous symptoms after steroid treatment. Concurrent chemoradiotherapy for patients with advanced NSCLC was well tolerated with acceptable toxicity and achieved higher response rates than the first study, but rather low compliance rate(7%) in this study is worrisome. We need to improve nutritional suppoert during treatment and to use G-CSF to improve leukopenia and if necessary, supportive care will given as in patients. Longer follow-up and larger sample size is needed to observe survival advantage.
Carcinoma, Non-Small-Cell Lung
;
Chemoradiotherapy
;
Chungcheongnam-do
;
Cisplatin
;
Compliance
;
Drug Therapy*
;
Follow-Up Studies
;
Granulocyte Colony-Stimulating Factor
;
Humans
;
Leukopenia
;
Lung
;
Lung Neoplasms
;
Neoplasm Metastasis
;
Pleural Effusion
;
Pneumonia
;
Prospective Studies
;
Radiation Pneumonitis
;
Radiotherapy*
;
Sample Size
;
Sepsis
;
Small Cell Lung Carcinoma*